株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脊髄損傷:パイプライン製品の分析

Spinal Cord Injury - Pipeline Review, H2 2017

発行 Global Markets Direct 商品コード 229793
出版日 ページ情報 英文 200 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.89円で換算しております。
Back to Top
脊髄損傷:パイプライン製品の分析 Spinal Cord Injury - Pipeline Review, H2 2017
出版日: 2017年10月17日 ページ情報: 英文 200 Pages
概要

脊髄損傷は、脊髄が身体的外傷を受けたものであると定義され、運動機能や感覚が失われたり障害が残ったりします。通常、身体的外傷や横断性脊髄炎、ポリオ、脊椎破裂、フリードライヒ運動失調症などによって引き起こされます。この疾患の症候は、背中に激しい痛みが起こる、首や頭、あるいは背中に圧迫感がある、体のどこかの力が抜けたり、感覚が無くなる、手、指、足、つま先がしびれたり感覚が無くなる、膀胱や腸のコントロールがきかなくなる、バランスを取り歩くのが困難になる、事故後に呼吸障害が起きたりします。

当レポートでは、脊髄損傷の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

脊髄損傷 概要

治療薬の開発

治療薬の評価

治療薬開発に従事している企業

薬剤プロファイル

休止中のプロジェクト

開発が中止された製品

製品開発のマイルストーン

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9859IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Spinal Cord Injury - Pipeline Review, H2 2017, provides an overview of the Spinal Cord Injury (Central Nervous System) pipeline landscape.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia. Signs and symptoms of spinal cord injury include extreme back pain or pressure in the neck, head or back, paralysis in any part of the body, numbness, tingling or loss of sensation in the hands, fingers, feet or toes, loss of bladder or bowel control, difficulty in walking and impaired breathing after injury.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Spinal Cord Injury - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Spinal Cord Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Spinal Cord Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 9, 8, 1, 29 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 15 and 2 molecules, respectively.

Spinal Cord Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Spinal Cord Injury (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Spinal Cord Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Spinal Cord Injury (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Spinal Cord Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Spinal Cord Injury (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Spinal Cord Injury (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Spinal Cord Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Spinal Cord Injury - Overview
  • Spinal Cord Injury - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Spinal Cord Injury - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Spinal Cord Injury - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Acorda Therapeutics Inc
  • Aevi Genomic Medicine Inc
  • Apollo Endosurgery Inc
  • Asterias Biotherapeutics Inc
  • Athersys Inc
  • BioArctic AB
  • BioAxone BioSciences Inc
  • Biogen Inc
  • CSL Ltd
  • CSPC Pharmaceutical Group Limited
  • Genervon Biopharmaceuticals LLC
  • Hemostemix Inc
  • Histocell SL
  • K-Stemcell Co Ltd
  • Kadimastem Ltd
  • Kringle Pharma Inc
  • MandalMed Inc
  • Mapreg SAS
  • Neuralstem Inc
  • Neuronax SAS
  • New World Laboratories Inc
  • Pharmicell Co Ltd
  • PixarBio Corp
  • RDD Pharma Ltd
  • RespireRx Pharmaceuticals Inc
  • SanBio Inc
  • Spectrum Pharmaceuticals Inc
  • Stemedica Cell Technologies Inc
  • TissueGene Inc
  • Tumorend LLC
  • Vertex Pharmaceuticals Inc
  • Vicore Pharma AB
  • Spinal Cord Injury - Drug Profiles
  • ABT-555 - Drug Profile
  • APO-1 - Drug Profile
  • ASTOPC-1 - Drug Profile
  • AX-007 - Drug Profile
  • BA-277 - Drug Profile
  • BA-434 - Drug Profile
  • C-21 - Drug Profile
  • Cell Therapy for Spinal Cord Injury - Drug Profile
  • Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile
  • Cellgram-SCI - Drug Profile
  • CHEC-9 - Drug Profile
  • chondroitinase ABC nanosphere - Drug Profile
  • CLR-01 - Drug Profile
  • CM-101 - Drug Profile
  • CX-1739 - Drug Profile
  • CX-717 - Drug Profile
  • Drug for Spinal Cord Injury - Drug Profile
  • Drugs to Inhibit ROCK for Spinal Cord Injury - Drug Profile
  • ES-135 - Drug Profile
  • Fusion Protein to Antagonize EPHA4 for Amyotrophic Lateral Sclerosis, Acute Spinal Cord Injury, Sepsis and Ischemia Reperfusion Injury - Drug Profile
  • Gene Therapy for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile
  • glyburide - Drug Profile
  • GM-603 - Drug Profile
  • HBN-1 - Drug Profile
  • HC-016 - Drug Profile
  • ICCN-100 - Drug Profile
  • immune globulin (human) - Drug Profile
  • IMS-001 - Drug Profile
  • IMS-002 - Drug Profile
  • JM-4 - Drug Profile
  • KP-100IT - Drug Profile
  • laflunimus - Drug Profile
  • LM-11A31BHS - Drug Profile
  • LPA-181 - Drug Profile
  • Lpathomab - Drug Profile
  • MAP-4343 - Drug Profile
  • Monoclonal Antibody to Inhibit Connexin 43 for Spinal Cord Injury - Drug Profile
  • NCP-01 - Drug Profile
  • Neu-2000 - Drug Profile
  • NeuroRelease SCI - Drug Profile
  • neurovitas - Drug Profile
  • NgR(310)ecto-Fc - Drug Profile
  • NOVO-117 - Drug Profile
  • NSI-566 - Drug Profile
  • NWL-53 - Drug Profile
  • NX-210 - Drug Profile
  • Oligonucleotide for Central Nervous System and Metabolic Disorders - Drug Profile
  • oxymetazoline hydrochloride - Drug Profile
  • Peptide to Inhibit CSPG for Spinal Cord Injury and Neurodegenerative Diseases - Drug Profile
  • PF-05285401 - Drug Profile
  • Proteins to Activate BGLAP for Spinal Cord Injury and Autoimmune Disorders - Drug Profile
  • Q-Cells - Drug Profile
  • R-801 - Drug Profile
  • Recombinant Chondroitinase to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile
  • SB-618 - Drug Profile
  • SB-623 - Drug Profile
  • SC-0806 - Drug Profile
  • Small Molecules for Spinal Cord Injury - Drug Profile
  • Small Molecules to Block Voltage-Gated Potassium Channel for Spinal Cord Injury and Multiple Sclerosis - Drug Profile
  • SPI-1620 - Drug Profile
  • Stem Cell Therapy for Central Nervous System Disorders - Drug Profile
  • Stem Cell Therapy for Neurodegenerative Diseases - Drug Profile
  • Stem Cell Therapy for Spinal Cord Injury - Drug Profile
  • Stem Cell Therapy for Spinal Cord Injury - Drug Profile
  • Stem Cell Therapy for Spinal Cord Injury, Alzheimer's Disease, Progressive Supranuclear Palsy and Cerebral Palsy - Drug Profile
  • Synthetic Peptide to Antagonize PTPRS for Spinal Cord Injury - Drug Profile
  • Synthetic Peptides to Activate SDF-1 Alpha for CNS Disorders and Infectious Disease - Drug Profile
  • TG-N - Drug Profile
  • UH-0113 - Drug Profile
  • UH-0213 - Drug Profile
  • VX-210 - Drug Profile
  • Xcel-hNu - Drug Profile
  • Xcel-hNuP - Drug Profile
  • Spinal Cord Injury - Dormant Projects
  • Spinal Cord Injury - Discontinued Products
  • Spinal Cord Injury - Product Development Milestones
  • Featured News & Press Releases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Spinal Cord Injury, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Spinal Cord Injury - Pipeline by AbbVie Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Acorda Therapeutics Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Aevi Genomic Medicine Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Apollo Endosurgery Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Asterias Biotherapeutics Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Athersys Inc, H2 2017
  • Spinal Cord Injury - Pipeline by BioArctic AB, H2 2017
  • Spinal Cord Injury - Pipeline by BioAxone BioSciences Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Biogen Inc, H2 2017
  • Spinal Cord Injury - Pipeline by CSL Ltd, H2 2017
  • Spinal Cord Injury - Pipeline by CSPC Pharmaceutical Group Limited, H2 2017
  • Spinal Cord Injury - Pipeline by Genervon Biopharmaceuticals LLC, H2 2017
  • Spinal Cord Injury - Pipeline by Hemostemix Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Histocell SL, H2 2017
  • Spinal Cord Injury - Pipeline by K-Stemcell Co Ltd, H2 2017
  • Spinal Cord Injury - Pipeline by Kadimastem Ltd, H2 2017
  • Spinal Cord Injury - Pipeline by Kringle Pharma Inc, H2 2017
  • Spinal Cord Injury - Pipeline by MandalMed Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Mapreg SAS, H2 2017
  • Spinal Cord Injury - Pipeline by Neuralstem Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Neuronax SAS, H2 2017
  • Spinal Cord Injury - Pipeline by New World Laboratories Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Pharmicell Co Ltd, H2 2017
  • Spinal Cord Injury - Pipeline by PixarBio Corp, H2 2017
  • Spinal Cord Injury - Pipeline by RDD Pharma Ltd, H2 2017
  • Spinal Cord Injury - Pipeline by RespireRx Pharmaceuticals Inc, H2 2017
  • Spinal Cord Injury - Pipeline by SanBio Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Spectrum Pharmaceuticals Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Stemedica Cell Technologies Inc, H2 2017
  • Spinal Cord Injury - Pipeline by TissueGene Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Tumorend LLC, H2 2017
  • Spinal Cord Injury - Pipeline by Vertex Pharmaceuticals Inc, H2 2017
  • Spinal Cord Injury - Pipeline by Vicore Pharma AB, H2 2017
  • Spinal Cord Injury - Dormant Projects, H2 2017
  • Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..2), H2 2017
  • Spinal Cord Injury - Dormant Projects, H2 2017 (Contd..3), H2 2017
  • Spinal Cord Injury - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Spinal Cord Injury, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top